CISATRACURIUM BESYLATE INJECTION
PFIZER CANADA ULC
This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.
Quick answers
Is CISATRACURIUM BESYLATE INJECTION discontinued in Canada?
Yes. The manufacturer has reported to Health Canada that CISATRACURIUM BESYLATE INJECTION 2MG has been permanently discontinued (last updated March 28, 2019). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.
Why is CISATRACURIUM BESYLATE INJECTION not available?
The reason the manufacturer reported: Business reasons.
Other Products Containing the Same Active Ingredient
These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.
Closest Matches
CISATRACURIUM BESYLATE INJECTION SINGLE DOSE
FRESENIUS KABI CANADA LTD
AJ-CISATRACURIUM
AGILA JAMP CANADA INC
CISATRACURIUM BESYLATE INJECTION MULTI-DOSE
FRESENIUS KABI CANADA LTD
CISATRACURIUM OMEGA SINGLE DOSE
OMEGA LABORATORIES LIMITED
CISATRACURIUM BESYLATE INJECTION
MYLAN PHARMACEUTICALS ULC
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE
OMEGA LABORATORIES LIMITED
What this means
Does this mean I need to switch medications right away?
Not necessarily right away, but this product will not be returning to the market.
What should I do?
Talk to your pharmacist or prescriber about your options well before your current supply runs out.
⚠ Possible Recall or Safety Alert
Health Canada has issued a recall or safety alert matching this product. This match is based on product name similarity and may not be exact — confirm against your specific lot number before taking action.
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde may be out of specification in the affected lots.
Low health risk
Possible match — not confirmed
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde is out of specification in the affected lots.
Low health risk
Possible match — not confirmed
DIN
02425718
Strength
2MG
Dosage Form
SOLUTION
Route
INTRAVENOUS
Compare with another product →
Shortage History
Other Products from PFIZER CANADA ULC
Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.
40MG · DIN 02511053
20MG · DIN 02511061
40MG · DIN 02511045
DIN 02544040
5MG · DIN 01947664
10MG · DIN 01947672
20MG · DIN 01947680
40MG · DIN 01947699
DIN 02237367
DIN 02237368
DIN 02237369
50MG · DIN 02401347